PMID: 11910268Mar 23, 2002Paper

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery

Journal of Clinical Psychopharmacology
Keith D WilnerCynthia K Titus

Abstract

The novel atypical antipsychotic ziprasidone has a pharmacologic profile notable for potent agonism of serotonin (5-HT)1A receptors, antagonism at 5-HT1D receptors, and reuptake inhibition of norepinephrine. 5-HT1A receptor agonism, in particular, suggests anxiolytic activity, and ziprasidone has shown preliminary efficacy in treating the symptoms of anxiety associated with psychotic disorders. In this study, the anxiolytic efficacy of ziprasidone was evaluated in nonpsychotic subjects who were anxious before undergoing minor dental surgery. We compared a single oral dose of 20 mg ziprasidone (N = 30) with that of 10 mg diazepam (N = 30) and placebo (N = 30) in a randomized, parallel-group, double-blind study. The peak anxiolytic effect of ziprasidone compared with that of placebo was similar to that of diazepam but had a later onset. At 3 hours postdose, the anxiolytic effect of ziprasidone was significantly greater than that of placebo (p < 0.05) and somewhat greater than that of diazepam. Diazepam showed a significantly greater anxiolytic effect than placebo at 1 hour (p < 0.05) but not at 3 hours. The sedative effect of ziprasidone was never greater than that of placebo, whereas that of diazepam was significantly greater th...Continue Reading

References

Jan 1, 1978·Clinical Pharmacokinetics·M MandelliS Garattini
Apr 1, 1992·Trends in Pharmacological Sciences·P R HartigR L Weinshank
Nov 1, 1991·Acta Psychiatrica Scandinavica·O Lingjaerde
Nov 1, 1991·Psychological Medicine·R M Norman, A K Malla
Dec 1, 1993·The Japanese Journal of Psychiatry and Neurology·Y Henmi
May 2, 1998·The Australian and New Zealand Journal of Psychiatry·S J Cosoff, R J Hafner
May 26, 1998·European Journal of Pharmacology·M E BeneytezJ Manzanares
Aug 5, 1998·International Clinical Psychopharmacology·J F Deakin
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan

❮ Previous
Next ❯

Citations

Oct 14, 2006·Rheumatology International·Elena P CalandreFernando Rico-Villademoros
Jul 30, 2005·Diabetes, Obesity & Metabolism·A J GoudieJ C G Halford
Nov 6, 2007·Expert Opinion on Emerging Drugs·Nirvana S Pillay, Dan J Stein
Feb 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nienke C C VulinkDamiaan Denys
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fernando Rico-VillademorosElena Pita Calandre
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
Feb 5, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Julia DiemerPeter Zwanzger
Feb 16, 2011·The International Journal of Neuropsychopharmacology·Luis H RipollLarry J Siever
Jun 28, 2005·International Journal of Psychiatry in Medicine·Steven A ColeAngela Smith
Oct 15, 2009·Journal of Psychopharmacology·Christopher GonanoBurkhard Gustorff
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anna M DeppingStefan Leucht
Jul 16, 2010·Journal of Clinical Psychopharmacology·Michael KellnerKlaus Wiedemann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here